Another Phase I clinical trial by Ahmed et al. targeting the tumor-associated antigen human epidermal growth factor receptor-2 (HER2) reported the outcome of treating 17 GBM patients with HER2-specific CAR T-cells (27). Here, ERBB2 is linked to glioblastoma.